Coeptis (COEP) Form 144 Filed for 5,000-Share Sale on NASDAQ

Rhea-AI Filing Summary

Form 144 notice for Coeptis Therapeutics Holdings, Inc. (COEP) reports a proposed sale of 5,000 common shares through Fidelity Brokerage Services LLC on 09/02/2025 on NASDAQ with an aggregate market value of $64,800.00. The filing shows total outstanding common shares of 4,820,317, indicating the shares to be sold are a small fraction of the outstanding stock.

The 5,000 shares were acquired on 10/31/2022 in a merger/acquisition transaction from the issuer. The filer reports no securities sold in the past three months. Several filer contact fields and issuer identification details are not provided in the content, so those specifics cannot be summarized from this document.

Insights

Securities Analyst

TL;DR: Routine insider sale notice: small block of shares, acquired in 2022, disclosed for regulatory compliance.

The filing documents a proposed sale of 5,000 common shares valued at $64,800 on 09/02/2025 via Fidelity. Given the issuer's reported outstanding shares of 4,820,317, the transaction represents approximately 0.10% of outstanding shares, a de minimis transfer in capital terms. The acquisition date of 10/31/2022 and method (merger/acquisition) are disclosed, and the filer confirms no sales in the prior three months. Missing filer identification and issuer contact details limit assessment of the seller's role or potential insider status. Overall, this appears to be a routine Form 144 disclosure required for certain proposed resale transactions rather than a company operational update.

Corporate Governance Expert

TL;DR: Compliance-focused disclosure with adequate transaction details but lacking filer and issuer identifiers.

The submission provides core transaction data: class (common), broker (Fidelity Brokerage Services LLC), sale date, quantity, aggregate value, acquisition date, and acquisition type (merger/acquisition). These elements satisfy key Rule 144 informational needs. However, the absence of explicit filer CIK, contact details, and issuer name/address in the provided content reduces transparency about the selling party and prevents confirmation of insider status or related-party considerations. From a governance standpoint, the document documents intent to sell but omits certain administrative identifiers in the excerpt supplied.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Fidelity Brokerage Services LLC 245 Summer Street Boston MA 02110	5000	64800.00	4820317	09/02/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	10/31/2022	Merger/Acquisition	Issuer			5000	10/31/2022	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)